Warfarin and Fluorouracil: Interaction Details

Brand names
Warfarin
CoumadinJantoven
Fluorouracil
TolakEfudexAdrucil +3 more
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Warfarin

Brand names
  • Coumadin
  • Jantoven

Fluorouracil

Brand names
  • Tolak
  • Efudex
  • Adrucil
  • Favlyxa
  • Carac
  • Fluoroplex

What Happens When You Take Warfarin With Fluorouracil

What can happen when they are taken together (rated Major)

Increased warfarin exposure and an increased risk of altered coagulation parameters and/or bleeding including death

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Patients taking coumarin-derivative together with capecitabine, doxifluridine, or fluorouracil (prodrugs of capecitabine) or tegafur (a of fluorouracil) have experienced changes in coagulation parameters and/or bleeding, in some cases fatal.5 In vivo, capecitabine is converted to fluorouracil.

When capecitabine, doxifluridine, fluorouracil, or tegafur is given with warfarin (a vitamin K and ), warfarin exposure may rise, which can change coagulation parameters and/or cause bleeding, and may lead to death. Such events can appear within days of starting treatment and as late as 1 month after capecitabine, doxifluridine, fluorouracil, or tegafur is stopped. Warfarin-related adverse reactions should be monitored more frequently, including the international normalized ratio ()3 and prothrombin time (PT), and the warfarin dose should be adjusted.4

The Warfarin and Fluorouracil Interaction, Explained

Fluorouracil can make warfarin stronger in your body, which raises the chance of bleeding. Warfarin is a , and fluorouracil (a cancer medicine, also used as a skin cream or injection) can slow down how your body clears it. Your blood can then get too thin, so you might bruise easily, have nosebleeds, or notice blood in your urine or stool.

This can show up within days of starting fluorouracil and may last for up to a month after you stop it. Your care team can manage this. They usually check your blood clotting test () more often and may adjust your warfarin dose. Keep taking your medicines as prescribed, and tell your pharmacist or doctor right away about any unusual bleeding.

Mechanism: Fluorouracil (and its prodrugs capecitabine, tegafur, doxifluridine) inhibits -mediated of warfarin (notably S-warfarin), increasing warfarin exposure, with effects on hemostasis. Fluorouracil is the active agent here, so the direction is increased effect.

  • Effect: supratherapeutic /PT prolongation and bleeding, including fatal events reported.
  • Onset: delayed; within days of initiation and up to 1 month after discontinuation.
  • Evidence: established. Severity: major.
  • Management: warfarin has a , so even small exposure changes matter. Monitor INR/PT more frequently, during therapy and for about a month after stopping, and adjust the warfarin dose individually. Counsel on bleeding signs.

See the 12 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Warfarin and Fluorouracil Interact

The likely mechanism

of -mediated of warfarin; effects on hemostasis

How Drug Interactions Work Six short figures, about a minute: how one drug can raise or lower another’s level, or add to or cancel its effect. See how it works 

How to Manage the Warfarin and Fluorouracil Interaction

Your care team can manage this combination, usually by checking your clotting tests more closely and tailoring your warfarin dose.

  • Keep taking both medicines exactly as prescribed. Do not change or stop either one on your own.
  • Expect more frequent (blood clotting) checks, both while using fluorouracil and for up to a month after it ends.
  • Your warfarin dose may need to be adjusted and individualized by your care team.
  • Tell your pharmacist or prescriber about any new bleeding, bruising, black stools, or blood in urine right away.
  • Make sure everyone treating you knows you take both.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Warfarin or Fluorouracil need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

14 reports from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: XELODA oral tablets, capecitabine oral tablets

    In a clinical study of four patients with cancer, chronic capecitabine 1250 mg/m(2) twice daily given with a single 20 mg dose of warfarin raised the mean S-warfarin by 57% and lowered its by 37%. In these 4 patients, the baseline corrected AUC rose 2.8-fold, and the maximum observed mean INR was 91% higher.3

  2. Report 2 · Study title

    Prescribing information: Teysuno oral capsules, tegafur gimeracil oteracil oral capsules

    Changes in coagulation parameters and/or bleeding, including fatal outcomes, have been reported in patients who received capecitabine, tegafur, or fluorouracil together with coumarin-derivative .5

  3. Report 3 · Study title

    Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer

    A study of four patients with advanced or metastatic breast or colon cancer showed a significant rise in S-warfarin exposure when capecitabine was coadministered. Each patient received a single 20 mg dose of warfarin on day 1, 8 days before capecitabine was started.

    From day 8 through day 70 they received three cycles of oral capecitabine 1250 mg/m2 twice daily for 14 days, each followed by a 7 day rest period. On day 61 (day 12 of the third cycle), a second single 20 mg warfarin dose was given.

    Warfarin (PK) and (PD) parameters were assessed 30 minutes before the dose and at 1, 2, 4, 8, 12, 24, 32, 48, 72, 96, and 144 hours after dosing on both day 1 and day 61. Comparing warfarin alone with warfarin plus capecitabine, the mean S-warfarin increased by 57% (90% CI, 32% to 88%), the was prolonged by 51% (90% CI, 32% to 74%), and S-warfarin fell by 36% (90% CI, 24% to 47%).

    The baseline corrected AUC in these subjects rose 2.8-fold, and the maximum observed mean INR rose by 91%. R-warfarin exposure was not significantly changed by capecitabine. Factor VII activity also appeared to increase, but the difference was not statistically significant (P=0.1204).6

  4. Report 4 · Study title

    Capecitabine-warfarin interaction

    A 59-year-old man receiving chronic warfarin for a mechanical mitral valve replacement needed a daily warfarin dose reduction of more than 85% over three cycles of capecitabine/irinotecan. He had stage IV colon cancer with metastasis, and prior therapy included fluorouracil/leucovorin and the FOLFOX 6 regimen.

    With a target of 2.5 to 3.5, he was taking 16% less warfarin by the end of the first capecitabine/irinotecan cycle. Later cycles required further warfarin reductions of up to 58%, and no confounding factors such as other drug interactions, vomiting, or weight loss were identified. Liver impairment could have been considered a cause of reduced warfarin , but when capecitabine/irinotecan was stopped, a higher warfarin dose was needed to keep the INR at the desired level.7

  5. Report 5 · Study title

    An adverse interaction between warfarin and capecitabine: a case report and review of literature

    This report describes two cases illustrating marked coagulopathy and resulting bleeding with coadministered warfarin and capecitabine. The first was a 91-year-old woman with adenocarcinoma of the rectum and metastases to the lungs and liver.

    She received capecitabine 2000 mg/m(2) per day in 2 divided doses for 2 weeks, followed by one week of rest. After 4 cycles, a CT scan showed a transluminal thrombus in the left femoral vein, and warfarin 2.5 mg per day was started to maintain an of 2 to 2.5.

    After 2 more capecitabine cycles she was hospitalized with rectal and vaginal bleeding, a PT of 72.9 seconds, and an INR above 10. Warfarin and capecitabine were both stopped immediately.

    Forty-eight hours after presentation, her PT was 15.6 seconds with an INR of 1.65. She received no further cancer therapy, and her coagulation parameters have stayed in the since discharge.8

  6. Report 6 · Study title

    An adverse interaction between warfarin and capecitabine: a case report and review of literature

    The second case in this report was a 72-year-old woman with recurrent metastatic breast cancer who was later diagnosed with pulmonary embolism and given warfarin 2.5 mg per day to maintain an of 2 to 3. After an 8 month progression-free interval, a bone scan showed progressive metastatic disease, and she started capecitabine 2000 mg/m2 per day in 2 divided doses for 14 days followed by 7 days of rest.

    After 2 cycles she was hospitalized with an H/H of 5.6 g/dL/16%, a PT above 100, and an INR above 10. Warfarin, capecitabine, and ibuprofen were stopped immediately.

    She received 4 units of fresh frozen plasma, 4 units of packed red blood cells, and 10 mg of vitamin K. Forty-eight hours after admission her vital signs were normal, her INR was 2.2, and her stool was guaiac negative.

    Chemotherapy was not resumed. Warfarin was restarted at 2.5 mg per day, and her coagulation parameters stayed in the normal range.8

  7. Report 7 · Study title

    An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature

    A 58-year-old man taking warfarin 1 mg/day to prevent catheter-associated thrombosis developed an asymptomatic PT elevation after fluorouracil and vinBLAStine were started. His PT before chemotherapy was 11.6 sec.

    For small cell lung cancer he received intravenous vinBLAStine 2 mg/day and intravenous fluorouracil 800 mg/day for 5 consecutive days at monthly intervals. PT was not measured with every cycle, but 16 days after the start of the last cycle it was elevated at 62.3 sec, and it fell to 48.8 sec the next day.

    Warfarin was stopped and intravenous phytonadione 10 mg was given the following day. Over the next week the PT continued to fall to 19.6, 16.8, and 14.1 sec. He remained well for several months but later died of brain metastases.9

  8. Report 8 · Study title

    Possible interactions between warfarin and antineoplastic drugs

    A 70-year-old woman treated with cycloPHOSphamide, methotrexate, and fluorouracil for breast cancer was started on warfarin and subsequently had an elevated PT by day 15 of 4 chemotherapy cycles; she also had gross hematuria on the first occasion and epistaxis on each occasion. On a stable warfarin dose her PT ranged from 8.2 to 21 sec.

    The PT rose to 44.2, 39, 31, and 29 sec by day 15 of each successive chemotherapy cycle, and returned to pretreatment levels within 48 to 72 hours. Epistaxis and hematuria resolved with warfarin discontinuation and dose reduction.1

  9. Report 9 · Study title

    Possible interactions between warfarin and antineoplastic drugs

    A 57-year-old woman treated with cycloPHOSphamide, methotrexate, and fluorouracil for breast cancer was started on warfarin and subsequently had an elevated PT and microscopic hematuria by day 15 of each cycle. She also had epistaxis once.

    Her PT ranged from 14.8 to 17.2 sec over 3 weeks, then rose to a range of 24.6 to 26 sec by day 15 of each later chemotherapy cycle. The PT returned to pretreatment levels within 48 hours.1

  10. Report 10 · Study title

    Possible drug interaction between warfarin and combination of levamisole and fluorouracil

    One report described a 73-year-old man with prosthetic mitral and aortic valve replacements who was stabilized on warfarin 22.5 mg weekly with a mean of 2.43. After colon resection for colon cancer, he received maintenance levamisole (50 mg every 8 hours for 3 days every other week) and fluorouracil (450 mg/m(2)/week).

    Within 4 weeks of starting the antineoplastic therapy, his INR rose from 3.04 to 39.56, and his warfarin was then reduced to 7.5 mg weekly. Because of a decline in neutrophil count, he stopped levamisole-fluorouracil for 5 weeks, during which his INR fell below therapeutic levels. When levamisole-fluorouracil was restarted, his PT again rose significantly.2

  11. Report 11 · Study title

    Warfarin-5FU interaction - a consecutive case series

    Five patients received warfarin and fluorouracil over a period of 3 years. The mean weekly warfarin dose was 40.66 mg before fluorouracil and 24 mg with fluorouracil. On average, all patients needed a 44% warfarin dose reduction.10

  12. Report 12 · Study title

    International normalized ratio fluctuation with warfarin-fluorouracil therapy

    warfarin and fluorouracil produced a fluctuating in a 60-year-old woman with colon cancer. Her chemotherapy consisted of 6 cycles of fluorouracil and leucovorin, each given for 5 consecutive days during a month.

    She was diagnosed with deep venous thrombosis in the left leg, and warfarin was started with a baseline INR of 1.1. In each chemotherapy cycle, the INR rose above the target range of 2 to 3 three to four weeks after the last fluorouracil and leucovorin dose.

    The INR peaked at 4.2 three weeks after the last cycle, and the total weekly warfarin dose was reduced from 9 mg/week to 7 mg/week. Four weeks after the final chemotherapy cycle ended, the INR dropped to 1.58.

    To maintain an INR of 2 to 3, the weekly warfarin dose had to be doubled from 7 mg/week to 14 mg/week. Fluorouracil may inhibit the synthesis of 2C9 and thereby inhibit warfarin .

    Close INR monitoring is recommended when warfarin is added to fluorouracil therapy. Warfarin dosage may need to be reduced by 20 to 70% during concomitant fluorouracil therapy and then increased within 30 days after fluorouracil is discontinued to keep the INR in the desired range.11

  13. Report 13 · Study title

    Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?

    Continuous-infusion fluorouracil-based chemotherapy combined with minidose warfarin (1 mg/day) has been shown to increase the incidence of abnormalities. Ninety-five cancer patients treated with continuous-infusion fluorouracil-based chemotherapy were evaluated.

    Of 488 INR determinations, 50 (10%) showed an INR above 1.5. Thirty-one patients (33%) had a significant INR elevation, and 6 of these had minimal elevations (between 1.18 and 1.5).

    Bleeding occurred in 8 patients (INR 1.34 to 8.8): epistaxis without gross blood loss in 6 patients and hematuria in 2 patients. The INR became elevated in 12 (57%) of 21 patients treated with the FOLFOX regimen, 11 (27%) of 40 patients treated with the de Gramont regimen, and 5 (26%) of 19 patients treated with the FOLFIRI regimen.

    Analysis of 80 patients treated with these regimens showed a statistically significant association between INR elevation and FOLFOX treatment (p = 0.041). The study showed that of warfarin and fluorouracil led to INR elevation in 33% of patients, and that 7 of the 8 patients who developed bleeding problems had an elevated INR.

    No relationship was found between INR alteration or bleeding and liver metastasis, function, age, performance status, number of prior chemotherapy regimens, or chemotherapy toxicity. Clinicians should regularly monitor the PT in patients receiving warfarin and fluorouracil.12

  14. Report 14 · Study title

    Prescribing information: XELODA oral tablets, capecitabine oral tablets

    administration of multiple doses of capecitabine (1000 mg/m(2) twice daily for 14 days) raised the of celecoxib (a ) by 28%, its by 24%, and its Ctrough by 30%.3

Warfarin and Fluorouracil: Common Questions

How serious is the Warfarin and Fluorouracil interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Warfarin and Fluorouracil interaction managed?

Your care team can manage this combination, usually by checking your clotting tests more closely and tailoring your warfarin dose. Keep taking both medicines exactly as prescribed. Do not change or stop either one on your own. Expect more frequent (blood clotting) checks, both while using fluorouracil and for up to a month after it ends. Your warfarin dose may need to be adjusted and individua… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "delayed". Effects tend to build up gradually over days to weeks.

How strong is the evidence for this interaction?

The evidence is graded "established". Well documented — supported by controlled studies or strong clinical data.

Ask About the Warfarin and Fluorouracil Interaction

Ask in your own words about taking Warfarin and Fluorouracil together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (12)

  1. Seifter EJ, Brooks BJ, & Urba WJ: Possible interactions between warfarin and antineoplastic drugs. Cancer Treat Rep 1985; 69(2):244-245.
  2. Scarfe MA & Israel MK: Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann Pharmacother 1994; 28:464-467. DOI
  3. Product Information: XELODA(R) oral tablets, capecitabine oral tablets. Genentech USA Inc (per FDA), South San Francisco, CA, 2022. DailyMed
  4. Product Information: FAVLYXA™ intravenous injection, fluorouracil intravenous injection. Avyxa Pharma, LLC (per FDA), Parsippany, NJ, 2026. DailyMed
  5. Product Information: Teysuno oral capsules, tegafur gimeracil oteracil oral capsules. Nordic Group BV (per EMA), Hoofddorp, The Netherlands, 2012.
  6. Camidge R, Reigner B, Cassidy J, et al: Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol 2005; 23(21):4719-4725. PubMed
  7. Janney LM & Waterbury NV: Capecitabine-warfarin interaction. Ann Pharmacother 2005; 39:1546-1551. PubMed
  8. Copur MS, Ledakis P, Bolton M, et al: An adverse interaction between warfarin and capecitabine: a case report and review of literature. Clin Colorectal Cancer 2001; 1(3):182-184.
  9. Brown MC: An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature. Chemotherapy 1999; 45(5):392-395. PubMed
  10. Kolesar JM, Johnson CL, Freeberg BL, et al: Warfarin-5FU interaction - a consecutive case series. Pharmacotherapy 1999; 19:1445-1449.
  11. Carabino J & Wang F: International normalized ratio fluctuation with warfarin-fluorouracil therapy. AM J Health-System Pharm 2002; 59:875. PubMed
  12. Masci G, Magagnoli M, Zucali A, et al: Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?. J Clin Oncol 2003; 21(4):736-739. DOI
Was this write-up helpful?

Other Serious Interactions of Warfarin and Fluorouracil

Also serious with Warfarin

Also serious with Fluorouracil

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Warfarin

With Fluorouracil

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data. This interaction.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks. This interaction.
  • UnspecifiedThe timing of this interaction is not well characterized.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.